Annji Pharmaceutical Co (ROCO:7754) ROC %: -152.36% (As of Dec. 2025)


ROCO:7754 Annji Pharmaceutical Co Ltd ROCO:7754
9 GF Score
Price NT$58.70
! 3 Warning Signs
View Full Analysis

What is Annji Pharmaceutical Co ROC %?

Annji Pharmaceutical Co ROCO:7754 -0.68% 9 ROC % is -152.36% as of Dec. 2025. GuruFocus rates ROCO:7754 with a GF Score™ of 9/100. The stock has 3 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Annji Pharmaceutical Co's annualized return on capital (ROC %) for the quarter that ended in Dec. 2025 was -152.36%.

As of today (2026-07-01), Annji Pharmaceutical Co's WACC % is 10.31%. Annji Pharmaceutical Co's ROC % is -115.47% (calculated using TTM income statement data). Annji Pharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Annji Pharmaceutical Co  (ROCO:7754) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Annji Pharmaceutical Co's WACC % is 10.31%. Annji Pharmaceutical Co's ROC % is -115.47% (calculated using TTM income statement data). Annji Pharmaceutical Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Annji Pharmaceutical Co ROC % Related Terms


Annji Pharmaceutical Co ROC % Historical Data

* Premium members only.

The historical data trend for Annji Pharmaceutical Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annji Pharmaceutical Co ROC % Chart

Annji Pharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROC %
-77.29 -95.08 -80.76 -82.04 -108.08

Annji Pharmaceutical Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROC % Get a 7-Day Free Trial -63.29 -93.20 -73.37 -97.06 -152.36
ROCO:7754
9GF Score
Annji Pharmaceutical Co Ltd ROCO:7754
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annji Pharmaceutical Co ROC % Calculation

Annji Pharmaceutical Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

ROC % (A: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2024 ) + Invested Capital (A: Dec. 2025 ))/ count )
=-369.369 * ( 1 - 0% )/( (456.91 + 226.593)/ 2 )
=-369.369/341.7515
=-108.08 %

where

Invested Capital(A: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1002.001 - 91.833 - ( 706.011 - max(0, 290.542 - 743.8+706.011))
=456.91

Invested Capital(A: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=590.109 - 96.514 - ( 348.468 - max(0, 102.773 - 369.775+348.468))
=226.593

Annji Pharmaceutical Co's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-382.99 * ( 1 - 0% )/( (276.143 + 226.593)/ 2 )
=-382.99/251.368
=-152.36 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=783.735 - 73.408 - ( 505.552 - max(0, 108.777 - 542.961+505.552))
=276.143

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=590.109 - 96.514 - ( 348.468 - max(0, 102.773 - 369.775+348.468))
=226.593

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -152.36% mean?
Annji Pharmaceutical Co (ROCO:7754) has a ROC % of -152.36% as of Dec. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Annji Pharmaceutical Co and its competitors.
Is Annji Pharmaceutical Co's ROC % too high?
Annji Pharmaceutical Co's current ROC % is -152.36%. Overall, Annji Pharmaceutical Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Annji Pharmaceutical Co's ROC % compare to VRTX and REGN?
Annji Pharmaceutical Co's ROC % of -152.36% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Annji Pharmaceutical Co and its competitors. Annji Pharmaceutical Co's current ROC % is -152.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annji Pharmaceutical Co stock overvalued right now?
Annji Pharmaceutical Co (ROCO:7754) has a current ROC % of -152.36%. The current ROC % is -152.36%. Annji Pharmaceutical Co's overall GF Score™ is 9/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Annji Pharmaceutical Co (ROCO:7754), the current ROC % is -152.36% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annji Pharmaceutical Co Business Description

Address Zhongxiao E. Raod, 16th Floor-6, No. 508, Sector 7, Nangang Distrist, Taipei, TWN, 115011
Annji Pharmaceutical Co Ltd is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy's disease, or SBMA (Spinal and bulbar muscular atrophy). Its pipeline products include AJ201, AJ302 and AJ303.
9GF Score

Get the complete analysis for ROCO:7754

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$58.70
Price